Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VP 20621

Drug Profile

VP 20621

Alternative Names: CDAD therapies - ViroPharma Incorporated; Non-toxigenic C difficile; Non-toxigenic Clostridium difficile; NTCD; NTCD - ViroPharma Incorporated; NTX - ViroPharma Incorporated; VP-20621

Latest Information Update: 02 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hines VA Hospital
  • Developer Shire ViroPharma
  • Class Antibacterials; Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Clostridium difficile infections

Most Recent Events

  • 02 Sep 2015 No recent reports on development identified - Phase-II for Clostridium difficile infections (Prevention) in USA, Belgium, Canada, Germany, Spain and Switzerland (PO)
  • 11 Mar 2014 ViroPharma is now called Shire ViroPharma
  • 24 Jan 2014 ViroPharma has been acquired by Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top